Skip to main content
Top
Published in: Abdominal Radiology 2/2014

01-04-2014

Liver adenomatosis: serial investigation on MRI

Authors: Saowanee Srirattanapong, Wirana Angthong, Bong Soo Kim, Paul Hideyo Hayashi, David A. Gerber, John T. Woosley, Jared Peacock, Anuruddika Ranatunga, Richard C. Semelka

Published in: Abdominal Radiology | Issue 2/2014

Login to get access

Abstract

Purpose

To describe the natural history of liver adenomatosis (LA), including complications and changes in lesion size over time.

Materials and methods

Eighteen patients with clinical diagnosis of LA were included. Clinical and biochemical information were collected. The initial and follow-up MR studies were reviewed retrospectively to determine change in lesion size and imaging features.

Results

Seventeen patients were women (94.4%). The mean age of the initial MR study was 37.0 years (18–52 years). The median size of the largest lesion was 6.7 cm (range 3.0–13.5 cm). Intratumoral bleeding was detected on MRI in 9 lesions, in 7 patients (38.8%). The median size for hemorrhagic lesions was 7.6 cm (range 4.1–13.5 cm). During the mean follow-up period of 29.4 (range 4–98) months, 10 patients had stable disease (55.6%), and 8 patients had tumor regression (44.4%). Of 8 patients who were followed without intervention, 3 patients (37.5%) had spontaneous regression. No malignant transformation or lesion progression was occurred.

Conclusion

During an over 2-year follow-up period, the majority of lesions of LA appeared to remain stable or showed tumor regression. Spontaneous tumor regression can be observed in approximately 37% of individuals in the age range of 28–53 years.
Literature
1.
go back to reference Dokmak S, Paradis V, Vilgrain V, et al. (2009) A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology 137:1698–1705PubMedCrossRef Dokmak S, Paradis V, Vilgrain V, et al. (2009) A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology 137:1698–1705PubMedCrossRef
2.
go back to reference Flejou J, Barge J, Menu Y, et al. (1985) Liver adenomatosis. An entity distinct from liver adenoma? Gastroenterology 89:1132PubMed Flejou J, Barge J, Menu Y, et al. (1985) Liver adenomatosis. An entity distinct from liver adenoma? Gastroenterology 89:1132PubMed
3.
go back to reference Bioulac-Sage P, Laumonier H, Couchy G, et al. (2009) Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology 50:481–489PubMedCrossRef Bioulac-Sage P, Laumonier H, Couchy G, et al. (2009) Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology 50:481–489PubMedCrossRef
4.
go back to reference Deneve JL, Pawlik TM, Cunningham S, et al. (2009) Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy. Ann Surg Oncol 16:640–648PubMedCrossRef Deneve JL, Pawlik TM, Cunningham S, et al. (2009) Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy. Ann Surg Oncol 16:640–648PubMedCrossRef
5.
go back to reference Svrcek M, Jeannot E, Arrive L, et al. (2007) Regressive liver adenomatosis following androgenic progestin therapy withdrawal: a case report with a 10-year follow-up and a molecular analysis. Eur J Endocrinol 156:617–621PubMedCrossRef Svrcek M, Jeannot E, Arrive L, et al. (2007) Regressive liver adenomatosis following androgenic progestin therapy withdrawal: a case report with a 10-year follow-up and a molecular analysis. Eur J Endocrinol 156:617–621PubMedCrossRef
6.
go back to reference Vetelainen R, Erdogan D, de Graaf W, et al. (2008) Liver adenomatosis: re-evaluation of aetiology and management. Liver Int 28:499–508PubMedCrossRef Vetelainen R, Erdogan D, de Graaf W, et al. (2008) Liver adenomatosis: re-evaluation of aetiology and management. Liver Int 28:499–508PubMedCrossRef
7.
go back to reference Raman SP, Hruban RH, Fishman EK (2013) Hepatic adenomatosis: spectrum of imaging findings. Abdom Imaging 38(3):474–481PubMedCrossRef Raman SP, Hruban RH, Fishman EK (2013) Hepatic adenomatosis: spectrum of imaging findings. Abdom Imaging 38(3):474–481PubMedCrossRef
8.
go back to reference Goodwin MD, Dobson JE, Sirlin CB, Lim BG, Stella DL (2011) Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents. Radiographics 31:1547–1568PubMedCrossRef Goodwin MD, Dobson JE, Sirlin CB, Lim BG, Stella DL (2011) Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents. Radiographics 31:1547–1568PubMedCrossRef
9.
go back to reference Rebouissou S, Bioulac-Sage P, Zucman-Rossi J (2008) Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol 48:163–170PubMedCrossRef Rebouissou S, Bioulac-Sage P, Zucman-Rossi J (2008) Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol 48:163–170PubMedCrossRef
10.
go back to reference Zucman-Rossi J, Jeannot E, Nhieu JT, et al. (2006) Genotype–phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 43:515–524PubMedCrossRef Zucman-Rossi J, Jeannot E, Nhieu JT, et al. (2006) Genotype–phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 43:515–524PubMedCrossRef
11.
go back to reference Bioulac-Sage P, Rebouissou S, Thomas C, et al. (2007) Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 46:740–748PubMedCrossRef Bioulac-Sage P, Rebouissou S, Thomas C, et al. (2007) Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 46:740–748PubMedCrossRef
12.
go back to reference Laumonier H, Bioulac-Sage P, Laurent C, et al. (2008) Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology 48:808–818PubMedCrossRef Laumonier H, Bioulac-Sage P, Laurent C, et al. (2008) Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology 48:808–818PubMedCrossRef
13.
go back to reference Ronot M, Bahrami S, Calderaro J, et al. (2011) Hepatocellular adenomas: accuracy of magnetic resonance imaging and liver biopsy in subtype classification. Hepatology 53:1182–1191PubMedCrossRef Ronot M, Bahrami S, Calderaro J, et al. (2011) Hepatocellular adenomas: accuracy of magnetic resonance imaging and liver biopsy in subtype classification. Hepatology 53:1182–1191PubMedCrossRef
14.
go back to reference Grazioli L, Federle MP, Ichikawa T, et al. (2000) Liver adenomatosis: clinical, histopathologic, and imaging findings in 15 patients. Radiology 216:395–402PubMedCrossRef Grazioli L, Federle MP, Ichikawa T, et al. (2000) Liver adenomatosis: clinical, histopathologic, and imaging findings in 15 patients. Radiology 216:395–402PubMedCrossRef
15.
go back to reference Bunchorntavakul C, Bahirwani R, Drazek D, et al. (2011) Clinical features and natural history of hepatocellular adenomas: the impact of obesity. Aliment Pharmacol Ther 34:664–674PubMedCrossRef Bunchorntavakul C, Bahirwani R, Drazek D, et al. (2011) Clinical features and natural history of hepatocellular adenomas: the impact of obesity. Aliment Pharmacol Ther 34:664–674PubMedCrossRef
16.
go back to reference Furlan A, van der Windt DJ, Nalesnik MA, et al. (2008) Multiple hepatic adenomas associated with liver steatosis at CT and MRI: a case–control study. Am J Roentgenol 191:1430–1435CrossRef Furlan A, van der Windt DJ, Nalesnik MA, et al. (2008) Multiple hepatic adenomas associated with liver steatosis at CT and MRI: a case–control study. Am J Roentgenol 191:1430–1435CrossRef
17.
go back to reference Kobayashi S, Sakaguchi H, Takatsuka M, et al. (2009) Two cases of hepatocellular adenomatosis treated with transcatheter arterial embolization. Hepatol Int 3:416–420PubMedCentralPubMedCrossRef Kobayashi S, Sakaguchi H, Takatsuka M, et al. (2009) Two cases of hepatocellular adenomatosis treated with transcatheter arterial embolization. Hepatol Int 3:416–420PubMedCentralPubMedCrossRef
18.
go back to reference Stoot JH, Coelen RJ, De Jong MC, Dejong CH (2010) Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB 12:509–522PubMedCentralPubMedCrossRef Stoot JH, Coelen RJ, De Jong MC, Dejong CH (2010) Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB 12:509–522PubMedCentralPubMedCrossRef
19.
go back to reference Arita J, Sugawara Y, Hashimoto T, et al. (2003) Liver resection in patients with Gilbert’s syndrome. Surgery 134:835–837PubMedCrossRef Arita J, Sugawara Y, Hashimoto T, et al. (2003) Liver resection in patients with Gilbert’s syndrome. Surgery 134:835–837PubMedCrossRef
20.
go back to reference Radu P, Atsmon J (2001) Gilbert’s syndrome—clinical and pharmacological implications. Isr Med Assoc J 3:593–598PubMed Radu P, Atsmon J (2001) Gilbert’s syndrome—clinical and pharmacological implications. Isr Med Assoc J 3:593–598PubMed
Metadata
Title
Liver adenomatosis: serial investigation on MRI
Authors
Saowanee Srirattanapong
Wirana Angthong
Bong Soo Kim
Paul Hideyo Hayashi
David A. Gerber
John T. Woosley
Jared Peacock
Anuruddika Ranatunga
Richard C. Semelka
Publication date
01-04-2014
Publisher
Springer US
Published in
Abdominal Radiology / Issue 2/2014
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-013-0056-y

Other articles of this Issue 2/2014

Abdominal Radiology 2/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.